National and Kapodistrian University of Athens, Aretaieio Hospital, Department of Anesthesiology, Athens, Greece.
National and Kapodistrian University of Athens, Aretaieio Hospital, Department of Anesthesiology, Athens, Greece.
Braz J Anesthesiol. 2021 Jul-Aug;71(4):454-457. doi: 10.1016/j.bjane.2021.02.036. Epub 2021 Mar 21.
Neuraxial hematoma is a rare complication of the epidural technique which is commonly used for high quality postoperative pain relief. In case of urgent initiation of multiple antithrombotic therapy, the optimal timing of epidural catheter removal and need for treatment modification may be quite challenging. There are no specific guidelines and published reports are scarce.
We present the uneventful removal of an indwelling epidural catheter in a patient who was put on emergency triple antithrombotic treatment with Low Molecular Weight Heparin (LMWH), aspirin and clopidogrel in the immediate postoperative period, due to acute coronary syndrome. In order to define the optimal conditions and timing for catheter removal, so as to reduce the risk of complications, various laboratory tests were conducted 3 hours after aspirin/clopidogrel intake. Standard coagulation tests revealed normal platelet count, normal prothrombin time and normal activated partial thromboplastin time, while Platelet Function Analysis (PFA-200) revealed abnormal values (increased COL/EPI and COL/ADP values, both indicating inhibition of platelet function). The anti-Xa level, estimated 4 hours after LMWH administration, was within therapeutic range. At the same time, Rotational Thromboelastometry (ROTEM) showed a relatively satisfactory coagulation status overall. The epidural catheter was removed 26 hours after the last dual antiplatelet dose and the next dose was given 2 hours after removal. Enoxaparin was withheld for 24 hours and was resumed after 6 hours. Neurologic checks were performed regularly for alarming signs and symptoms suggesting development of an epidural hematoma. No complications occurred.
Point-of-care coagulation and platelet function monitoring may provide a helpful guidance in order to define the optimal timing for catheter removal, so as to reduce the risk of complications. A case-specific management plan based on a multidisciplinary approach is also important.
椎管内血肿是硬膜外技术的一种罕见并发症,该技术常用于高质量的术后止痛。如果需要紧急启动多种抗血栓治疗,那么移除硬膜外导管的最佳时机和是否需要治疗调整可能极具挑战性。目前尚无具体指南,相关的已发表报道也很少。
我们成功地为一名患者移除了留置的硬膜外导管,该患者在急性冠状动脉综合征后,立即接受了紧急三联抗血栓治疗,包括低分子肝素(LMWH)、阿司匹林和氯吡格雷。为了确定导管移除的最佳条件和时机,以降低并发症风险,在服用阿司匹林/氯吡格雷 3 小时后进行了各种实验室检查。常规凝血试验显示血小板计数正常、凝血酶原时间正常和活化部分凝血活酶时间正常,而血小板功能分析(PFA-200)显示异常值(COL/EPI 和 COL/ADP 增加,均表明血小板功能抑制)。LMWH 给药后 4 小时估计的抗 Xa 水平处于治疗范围内。同时,旋转血栓弹性测定(ROTEM)显示总体凝血状态相对满意。在最后一次双联抗血小板剂量后 26 小时移除硬膜外导管,并在移除后 2 小时给予下一次剂量。依诺肝素停用 24 小时,6 小时后恢复使用。定期进行神经检查,以发现提示硬膜外血肿发展的警示症状和体征。未发生并发症。
即时凝血和血小板功能监测可能有助于确定导管移除的最佳时机,从而降低并发症风险。基于多学科方法的个体化管理方案也很重要。